The multicenter phase III randomized EPIC trial (ponatinib vs. imatinib in 307 treatment-naive CML) showed significantly higher rates of MMR (41% vs. 18%) and MR4.5, which was defined as BCR-ABL1 ≤ 0.0032% IS [50] (15% vs. 0) at any time for patients treated on the ponatinib arm. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.